Hydrocodone is a semisynthetic opioid medication that is widely used as an analgesic and antitussive. Since 2004 it has been the most commonly prescribed drug in the United States and is often misused as a drug of abuse. Hydrocodone is frequently encountered in the postmortem setting, both as a cause of death and incidentally. Unfortunately, information regarding the concentrations of hydrocodone found with chronic high-dose use is lacking, and interpretation of postmortem concentrations can be difficult. A retrospective review of postmortem and BDriving under the Influence[ (DUI) cases in Bexar County Texas in which hydrocodone was present was conducted. The cases were included in the study if they fit the criteria of belonging to 1 of 3 categories: the hydrocodone either caused or was the main contributor to death; the hydrocodone was incidental and definitively did not cause or contribute to death; and the DUI cases. The average hydrocodone concentration in the cases where the hydrocodone caused death was 0.47 mg/L (median, 0.38 mg/L). The average hydrocodone concentration in cases where it was incidental to death was 0.15 mg/L (median, 0.08 mg/L). The average hydrocodone concentration in the DUI cases was 0.09 mg/L (median, 0.08 mg/L). Analysis showed the possibility of postmortem redistribution as well as significant overlap of the concentrations noted in the different groups. Given that no definitive lethal concentration could be delineated, it is recommended that each hydrocodone case encountered be assessed individually to include a thorough medical record review to accurately interpret hydrocodone concentrations. It has also been shown that concentrations as high as 0.3 mg/L peripherally and 1.4 mg/L centrally can be present and not result in death. In addition, further research into hydrocodone concentrations with chronic use and hydrocodone metabolism is necessary.
H ydrocodone is a semisynthetic opioid first derived from codeine in the 1920s as an analgesic and antitussive. It shows 2 to 8 times the potency of codeine and is currently a Schedule II medication. 1 Hydrocodone is most commonly found in preparations combined with acetaminophen (Vicodin, Norco, Lorcet, and Lortab), although it can also be combined with ibuprofen (Vicoprofen) or guaifenesin (Hycotuss). Since 2004 it has been prescribed more each year than any other medication in the United States. 2 It is widely used to treat both acute and chronic pain as well as being commonly misused as a drug of abuse.
Hydrocodone has a volume of distribution of 3.3 to 4.7 L/kg and a half-life of 3.5 to 6.2 hours. 1, 3, 4 Peak concentrations, averaging 0.02 to 0.05 mg/L, are achieved 60 to 100 minutes after acute dosing. 1, 3 Hydrocodone is metabolized by the CYP450 system and is a minor metabolite of codeine, although it is often seen only in urine after codeine use. The main active metabolite of hydrocodone, hydromorphone, is created via CYP2D6 by O-demethylation of the parent molecule. Hydromorphone has been shown to have an approximately 30 times greater affinity for the K-opioid receptor than hydrocodone. 5 Norhydrocodone is the other major metabolite of hydrocodone and its creation though N-demethylation is catalyzed by CYP3A4. Approximately 40% of hydrocodone is metabolized through other pathways including reduction at the 6-keto position and fecal, biliary, intestinal, and renal elimination. 5 Unfortunately, even though hydrocodone use is so prevalent, data regarding its pharmacokinetic properties with chronic use are lacking. Many clinicians do not consider hydrocodone tolerance a concern since they feel acetaminophen is the doselimiting component of long term hydrocodone use (Eckmann M, personal communication, August 18, 2009). Ackermann and Ahmad studying the effects of cigarette smoking on hydrocodone concentrations, 6 and Jannetto and Bratanow 7 reviewing the pharmacogenomics of hydrocodone found hydrocodone concentrations in chronic users to be comparable to those found in the acute setting with concentrations ranging from 0.004 to 0.04 mg/L. Forensic studies, however, have shown that postmortem concentrations can be as high as 2.56 mg/L in individuals where hydrocodone was not considered a factor in the death. 8 This conflicting information makes the interpretation of postmortem hydrocodone results difficult. In addition, hydro-codone_s relatively high volume of distribution suggests it could possibly undergo significant postmortem redistribution, making interpretation even more difficult.
MATERIALS AND METHODS
A retrospective review was performed to identify all cases in which hydrocodone was detected at the Bexar County Medical Examiners Office (BCMEO) between January 1998 and September 2009. The cases were further reviewed to ascertain those cases where hydrocodone definitely did not cause or contribute to death and those cases where hydrocodone was the cause or main contributor to death. In addition, the BCMEO performs blood testing on suspected BDriving Under the Influence[ cases for the local police agencies, and those cases were reviewed for the presence, and concentration, of hydrocodone.
For each case, the concentrations of both hydrocodone and acetaminophen were analyzed. The source of each sample was categorized as central (heart or subclavian), peripheral (femoral), cavity, and unknown. The data analysis performed regarding the specimen source compared only known peripheral versus central samples as defined; the unknown and cavity samples as well as any potentially contaminated specimens were not included in the analysis. Statistical analysis was performed using the Mann-Whitney U test.
RESULTS
A total of 97 medical examiner cases and 16 driving under the influence cases were identified that met inclusion parameters for the study. Of these, 39 cases were found where hydrocodone was believed to have either caused or have been the main contributor of death and 58 cases were found where hydrocodone was present but was believed to not have caused or contributed to death. A detailed summary of the case types follows.
Group 1: Hydrocodone Caused or Was Main Contributor to Death
There were a total of 39 cases found which met the criteria that hydrocodone either caused or was the main contributor to death. The average hydrocodone concentration was 0.47 mg/L (median, 0.38 mg/L; range, 0.07Y2.1 mg/L). The average acetaminophen concentration was 60.3 mg/L (median, 37.9 mg/L; range, 0Y311.5 mg/L). The majority (75%) of cases had hydrocodone concentrations greater than 0.07 mg/L. The central and peripheral blood concentrations did not show a statistically significant difference (Table 1 ).
In 32 cases (82%), at least one additional drug, other than acetaminophen, was present and in 15 cases (38.5%) two or more drugs were present. In only three cases, however, was the other drug present at a significant enough concentration that it was believed to contribute to death. In all three cases, the additional drug present was ethanol and the concentrations ranged from 0.15 to 0.26 g/dL. The prevalence of the other drugs found is summarized in Table 2 . Anxiolytics and antidepressants were the most common drug types found in combination with hydrocodone, followed by antihistamines and ethanol.
Seven cases (18%) had no other drugs present. In these cases, the average hydrocodone concentration was 0.46 mg/L (median, 0.53 mg/L; range, 0.19Y0.83 mg/L), with an average acetaminophen concentration of 91.2 mg/L (median, 42 mg/L; range, 0Y311.5 mg/L). Analysis failed to show a statistically significant difference between the hydrocodone concentrations in the Bpure[ cases versus those with other drugs present (P = 0.96).
Group 2: Hydrocodone Did Not Cause or Contribute to Death
There were a total of 58 cases found in which hydrocodone was present but did not cause or contribute to death. A summary of the causes of death in these cases is shown in Table 3 . Gunshot wounds were the most common cause of death, followed by blunt force injuries. Stab wounds, pulmonary emboli, cardiac tamponade (2 cases), and dissecting aortic aneurysm accounted for the remaining cases.
The hydrocodone concentrations found in cases where the hydrocodone did not cause or contribute to death is summarized in Table 4 . The average hydrocodone concentration was 0.15 mg/L (median, 0.08 mg/L; range, 0.02Y1.4 mg/L). The average acetaminophen concentration was 18.7 mg/L (median, 14.7 mg/L; range, 0Y112.8 mg/L). The majority (75%) of cases had hydrocodone concentrations less than 0.16 mg/L. Statistical analysis showed a significant difference between the peripheral and central blood hydrocodone concentrations within this group (P = 0.01).
In 49 cases (84.5%), at least one additional drug, besides acetaminophen, was present and in 25 cases (43%) two or more drugs were present. The prevalence of the other drugs found is summarized in Table 5 . Anxiolytics, antidepressants, and other opiates/opioids were the most common drug types found in combination with hydrocodone, followed by stimulants/ sympathomimetics and ethanol.
Eight cases (14%) had no other drugs present. In these cases, the average hydrocodone concentration was 0.12 mg/L (median, 0.08 mg/L; range, 0.02Y0.33 mg/L). Accurate analysis regarding the acetaminophen concentrations in these cases could not be performed. In two cases, acetaminophen was not detected. In one case, testing for acetaminophen was not performed. In four cases acetaminophen was present but not quantified and in one case the concentration was found to be 11.4 mg/L. Analysis failed to show a statistically significant difference between the hydrocodone concentrations in the Bpure[ cases versus those with other drugs present (P = 0.64).
Group 3: DUI Cases
Review of the DUI cases performed at the BCMEO revealed 16 cases where hydrocodone was present. The hydrocodone concentration data are summarized in Table 6 . The average hydrocodone concentration was 0.09 mg/L (median, 0.08 mg/L; range, 0.03Y0.17 mg/L). Unfortunately, the presence or absence of other drugs could not be analyzed for this group because full toxicologic screening was not necessarily performed on every case. However, in no case where full toxicology was performed was hydrocodone the only drug present (ie, additional intoxicants were always present when testing was performed).
Comparison of Groups
Statistical analysis showed a significant difference between the hydrocodone concentrations of group 1 when compared with both groups 2 and 3 (P G 0.001). Analysis also showed a significant difference between the acetaminophen concentrations between group 1 when compared with groups 2 and 3 (P G 0.001). Analysis comparing the hydrocodone concentrations of groups 2 and 3 failed to show a significant difference (P = 0.49).
DISCUSSION
As stated previously, hydrocodone concentrations are believed to be of little use in the clinical setting, as the usefulness of high-dose hydrocodone therapy is considered to be limited by the acetaminophen component. However, in the forensic setting, elevated concentrations of hydrocodone are often found in cases of traumatic death where hydrocodone could not have contributed to death. In this study, the median hydrocodone concentration found in traumatic deaths, 0.08 mg/L, was 12 times greater than the upper limit of the therapeutic range for hydrocodone. This leaves the forensic pathologist questioning how then should elevated hydrocodone concentrations be interpreted.
This study highlights that the specimen source is one variable which may affect interpretation. Hydrocodone may undergo significant postmortem redistribution as evidenced by the statistically significant difference between the central and peripheral blood concentrations in group 2. Although this same finding was not evident in group 1, it may have been a result of the small number of centrally drawn samples in this group.
Both this study and previous studies have shown considerable overlap between hydrocodone concentrations that cause death and those where it did not contribute. This study found an average and median concentration of hydrocodone in cases where the hydrocodone caused death to be 0.47 and 0.38 mg/L, respectively, with a range of 0.07 to 2.1 mg/L. This is consistent with Spillers study where he found, in 17 individuals dying from intoxication with hydrocodone, the average hydrocodone concentration to be 0.53 mg/L with a median of 0.4 mg/L and a range of 0.12 to 1.6 mg/L. 9 He also found that the majority of cases (65%) had hydrocodone concentrations greater than or equal to 0.5 mg/L, 9 which is significantly higher than the 0.07 mg/L majority found in this study. Baker and Jenkins (2008) , in their study addressing postmortem hydrocodone concentrations, reviewed 54 cases where hydrocodone caused or contributed to death and found that hydrocodone concentrations ranged from 0.012 to 1.66 mg/L with 42% of cases being 90.2 mg/L. 8 In addition, they had seven cases where no other drugs were present, and the concentration of hydrocodone ranged from 0.07 to 1.66 mg/L, 8 a broader range than that seen in this study.
For cases where hydrocodone neither caused nor contributed to death, this study found an average hydrocodone concentration of 0.15 mg/L with a median of 0.08 mg/L and a range of 0.02 to 1.4 mg/L. This is comparable to the study performed by Baker and Jenkins that analyzed 115 cases where hydrocodone was present incidentally and was not believed to cause death. 8 In their study, the mean hydrocodone concentration was 0.09 mg/L with a range from 0.01 to 2.56 mg/L. 8 Baker and Jenkins also reported that 20 cases had concentrations 90.2 mg/L and 2 cases had concentrations 91 mg/L. 8 In this study, 25 cases were Q0.1 mg/L and 12 were 90.2 mg/L. Hydrocodone is metabolized by the CYP450 enzyme system, specifically 2D6 and 3A4. Both of these enzymes have shown genetic variability which can affect the metabolizer status of an individual (ie, poor vs. extensive metabolizers). Poor metabolizers may develop higher concentrations of hydrocodone when taken chronically allowing for tolerance to develop and a relative resistance to these concentrations. In addition, extensive metabolizers may create increased concentrations of hydromorphone, which has been shown to have greater activity than hydrocodone, resulting in death at decreased hydrocodone concentrations. Otton et al 4 and Jannetto and Bratanow 7 have both studied the issue of hydrocodone metabolizer status as it pertains to CYP2D6. Jannetto and Bratanow found no significant difference in the hydrocodone concentrations of extensive and intermediate metabolizers but the data was limited (only four extensive metabolizers, three intermediate, and no poor metabolizers) and markedly skewed. 7 Like Janetto and Bratanow, Otton et al failed to find a significant difference between hydrocodone concentrations of extensive versus poor metabolizers, although, a significant difference between the hydromorphone concentrations was found. 4 However, Otton et al_s study was again limited by number (only five extensive metabolizers and 
DUI Cases
No. cases 16 Average 0.09 mg/L Median 0.08 mg/L Range 0.03Y0.17 mg/L six poor metabolizers) and the data analysis was performed using a method which appears to have been inappropriate for the data given. This study, in combination with both Spillers, and Baker and Jenkins, illustrates the variability in postmortem hydrocodone concentrations and the overlap between those concentrations which may result in death and those which may not. This study has shown that concentrations of hydrocodone can be as high as 1.4 mg/L centrally and 0.32 mg/L peripherally and not cause death. Concentrations as high as 0.17 mg/L were also seen in individuals operating motor vehicles, although how well the vehicle was being operated is not known. In the majority of cases where the hydrocodone resulted in death, concentrations were 90.1 mg/L; although, 42% of cases where hydrocodone did not cause death had concentrations Q0.1 mg/L. Thus, a thorough death investigation including a complete autopsy and review of the decedent_s medical history should be undertaken before interpreting the significance of hydrocodone concentrations and determining whether hydrocodone caused or contributed to death. In addition, further research should be conducted into the possible role of pharmacogenetics in this variability.
